NKGen Biotech
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NKGen Biotech and buy or sell other stocks, ETFs, and their options commission-free!About NKGN
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression.
CEOPaul Y. Song
CEOPaul Y. Song
Employees63
Employees63
HeadquartersSanta Ana, California
HeadquartersSanta Ana, California
Founded2017
Founded2017
Employees63
Employees63
NKGN Key Statistics
Market cap12.81M
Market cap12.81M
Price-Earnings ratio-0.12
Price-Earnings ratio-0.12
Dividend yield—
Dividend yield—
Average volume237.19K
Average volume237.19K
High today$0.2898
High today$0.2898
Low today$0.265
Low today$0.265
Open price$0.265
Open price$0.265
Volume4.33K
Volume4.33K
52 Week high$1.75
52 Week high$1.75
52 Week low$0.0983
52 Week low$0.0983
People also own
Based on the portfolios of people who own NKGN. This list is generated using Robinhood data, and it’s not a recommendation.